News and Trends 14 Nov 2017 Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low …RNA technology to treat central nervous system (CNS) disorders. Update (14/11/2017): Included the expected amount to be raised after ProQR issued a press release. Images via Puslatronik /Shutterstock; Yahoo Finance… November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Newron reports ‘striking’ schizophrenia study results …an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant… February 16, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy …another €6M a year. Among them are the leaders of the liver metabolism and CNS therapeutic areas, programs which will be eliminated. UniQure’s manufacturing will now be consolidated in its… November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Jan 2025 Top 19 most-performing biotech stocks of 2024 …central nervous system (CNS) to treat a range of neurological and psychiatric disorders. At the core of Bright Minds’ technology is its work on the serotonin 5-HT receptor family, particularly… January 27, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Weekly Roundup 24 Nov 2023 Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA …will go towards the development of Alto’s central nervous system (CNS) candidates. This will be done through placebo-controlled clinical trials that are set to end in 2025. Investment was led… November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2023 Microbiome: are we ready for third generation live biotherapeutics? …(GI) infections and conditions, to boosting the potency of immuno-oncology treatments and perhaps in the future, the treatment of central nervous system (CNS) and metabolic diseases. It’s not been an… October 25, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug …once the results of the study are fully understood at the upcoming Alzheimer’s Association International Conference in July, though. Jan Poth, head of CNS diseases at Boehringer, appears to have… February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Jan 2024 A new chapter in cell therapy: engineered B cells reach the clinic for the first time …therapeutics have application – from lysosomal storage diseases to obesity/diabetes, CNS disorders, oncology, and beyond,” commented Ainsworth. Ainsworth also explained that one of the main benefits of engineered B cells… January 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Dec 2023 Seven companies shaping the future of precision medicine …company Alto Neuroscience secured $45 million in a series C funding round last month, which it will use to support the clinical development of its central nervous system (CNS) candidates…. December 14, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2025 Psychedelics sans side effects: neuroplastogens gain ground …central nervous system (CNS) engagement. Preclinical data demonstrated that DLX-001 increased dendritic spine density in the neurons in the prefrontal cortex, the region located at the front of the frontal… June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Jan 2020 How to Spot a Biotech Winner: Investment Lessons from Sofinnova …have been created on RNA editing. There will be an IP battle, I suspect, not unlike CRISPR has seen. There’s this permanent pendulum. As you know, CNS was completely off…. January 15, 2020 - 10 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Aug 2023 Six Toronto-based biotech companies to watch this year …like Deep Genomics having developed a portfolio of candidates, some of which are being evaluated as therapies for central nervous system (CNS)-related disorders, the city’s research and development sector is… August 17, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email